Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer

Journal of Ovarian Research
Maureen L DrakesPatrick J Stiff

Abstract

Ovarian cancer is the major cause of death among gynecologic cancers with 75% of patients diagnosed with advanced disease, and only 20% of these patients having a survival duration of five years. Treatments blocking immune checkpoint molecules, programmed cell death (PD-1) or its ligand PD-ligand- I (PD-L1) have produced a beneficial and prolonged effect in a subgroup of these patients. However, there is debate in the literature concerning the prognostic value of the expression of these molecules in tumors, with immunotherapy responsiveness, and survival. We evaluated the immune landscape of the ovarian tumor microenvironment of patients, by measuring the impact of the expression of tumor PD-1, PD-L1 and infiltrating lymphocytes on stage and grade of tumors and survival, in a cohort of 55 patients with gynecologic malignancies. Most patients under study were diagnosed with advanced disease ovarian cancer. Our studies revealed that a low density of PD-1 and of PD-L1 expressing cells in tumor tissue were significantly associated with advanced disease (P = 0.028 and P = 0.033, respectively). Moreover, PD-L1 was expressed significantly more often in high grade tumors (41.5%) than in low grade tumors of patients (7.7%) (P = 0.040). ...Continue Reading

References

Aug 1, 1995·The Journal of Experimental Medicine·M F Krummel, J P Allison
Dec 30, 2006·Cancer Immunology, Immunotherapy : CII·Christian Blank, Andreas Mackensen
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Junzo HamanishiShingo Fujii
Mar 17, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·R Houston ThompsonEugene D Kwon
Jul 4, 2007·International Immunology·Taku Okazaki, Tasuku Honjo
Jan 5, 2008·Annual Review of Immunology·Mary E KeirArlene H Sharpe
Feb 22, 2008·Proceedings of the National Academy of Sciences of the United States of America·F Stephen HodiGlenn Dranoff
May 5, 2009·Nature Reviews. Rheumatology·Jagadeesh Bayry
Feb 11, 2010·Gynecologic Oncology·Refika YigitRuurd Torensma
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jan 24, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kaoru AbikoIkuo Konishi
Dec 4, 2013·Cancer Immunology, Immunotherapy : CII·Christian J MaineSadaf Ghaem-Maghami
Apr 10, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Janis M TaubeRobert A Anders
Oct 25, 2014·Therapeutic Advances in Medical Oncology·Daniela LuveroJonathan A Ledermann
Nov 28, 2014·Nature·Matthew M GubinRobert D Schreiber
Mar 26, 2015·Journal for Immunotherapy of Cancer·Cariad ChesterHolbrook Kohrt
Apr 11, 2015·Cancer Cell·Suzanne L TopalianDrew M Pardoll
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Aug 4, 2015·Journal of Immunology Research·Francesca De FelicePierluigi Benedetti Panici
Sep 10, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Junzo HamanishiIkuo Konishi
Sep 12, 2015·Science·Eliezer M Van AllenLevi A Garraway
Nov 13, 2015·American Journal of Clinical Oncology·Elizabeth I Buchbinder, Anupam Desai
Apr 9, 2016·International Immunology·Junzo HamanishiIkuo Konishi
Jun 9, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe MassardNeil H Segal
Nov 7, 2016·Clinical Lung Cancer·Erna-Elise PaulsenTom Donnem
Dec 3, 2016·Gynecologic Oncology Research and Practice·Stéphanie L GaillardBradley Monk
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Apr 6, 2017·Journal of Biomedical Science·Yoshiko IwaiTasuku Honjo
Apr 20, 2017·Genome Medicine·Zachary R ChalmersGarrett M Frampton
May 13, 2017·Cell Reports·Angel Garcia-DiazAntoni Ribas

❮ Previous
Next ❯

Citations

Dec 6, 2019·Current Opinion in Obstetrics & Gynecology·Curtis D ChinJianyu Rao
Jun 18, 2020·Diagnostics·Mianxin ChewGeok Chin Tan
Jun 20, 2020·Scandinavian Journal of Immunology·Emmanuelle BenardSébastien Wälchli
Jun 13, 2020·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Estrid HøgdallTorben Steiniche
Nov 5, 2019·Frontiers in Oncology·Oliviero MarinelliMassimo Nabissi
Jun 19, 2019·International Journal of Molecular Sciences·Eleonora GhisoniGiorgio Valabrega
Oct 13, 2020·Cancer Biology & Therapy·Fangran LiuGuoxiong Xu
Mar 18, 2021·European Journal of Histochemistry : EJH·Caroline Eymerit-MorinEmile Darai
Aug 24, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Shufeng DuanCaixia Chen
May 12, 2021·Apoptosis : an International Journal on Programmed Cell Death·Zhang AichenTong Lingling
Jun 8, 2021·Acta Pharmaceutica Sinica. B·Seyed Hossein KiaieBehzad Baradaran
Sep 4, 2021·Journal of Cancer Research and Clinical Oncology·Sara CorvignoAnil K Sood

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies

Software Mentioned

SAS

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

© 2022 Meta ULC. All rights reserved